Insys Therapeuti (NASDAQ:INSY) is one of today’s worst performing low-priced stocks, down 69.7% to $1.09 on 1.5x average daily volume. Thus far today, Insys Therapeuti has traded 631,000 shares, vs. average volume of 412,000 shares per day. The stock has underperformed the Dow (-69.7% to the Dow’s -1.1%) and underperformed the S&P 500 (-69.7% to the S&P’s -1.1%) during today’s trading.
In the past 52 weeks, Insys Therapeuti share prices have been bracketed by a current low of $1.09 and a high of $11.65 and are now at $1.09. In the last five trading sessions, the 50-day moving average (MA) has fallen 4.4% while the 200-day MA has slid 1.5%.
Insys Therapeutics, Inc. develops cancer support drugs. The Company support care candidates include a fast-acting sublingual spray for cancer pain and a dronabinol product used to treat chemotherapy-induced nausea and vomiting and to stimulate appetite in AIDS patients.
Potential upside of 744.0% exists for Insys Therapeuti, based on a current level of $1.09 and analysts’ average consensus price target of $9.20. The stock should run into initial resistance at its 50-day moving average (MA) of $4.68 and subsequent resistance at its 200-day MA of $6.18.
SmarTrend recommended that its subscribers protect gains by selling shares of Insys Therapeuti on March 8th, 2019 by issuing a Downtrend alert when the shares were trading at $5.15. Since that call, shares of Insys Therapeuti have fallen 30.0%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.
Write to SmarTrend at email@example.com
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.MySmarTrend.com
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.MySmarTrend.com/signup